NOTCH1 and T-cell acute lymphoblastic leukemia: It is known that in T-cell acute lymphoblastic leukemia (T-ALL), where more than 50% of patients have activating NOTCH1 mutations, GSIs efficiently inhibit Notch1 oncogenic protein [128].